For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Antibody Drug Conjugates are highly effective biopharmaceutical medications designed as a targeted therapy for cancer treatment.
Scope of the Report:
This report focuses on the Antibody Drug Conjugates in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The preparation process of ADC's involves great difficulty, inspite of these hurdles recently approved ADC's have proved their worth for treatment of cancer. Thus, there is a strong pipeline of ADC's that promises revolutionary changes in area of targeted therapy for cancer treatment. This market is driven by elements such as continuous improvement in the clinical data and technological advancements in the field of drug development shelling out innovative drugs into the market.
The worldwide market for Antibody Drug Conjugates is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- F. Hoffman-La Roche
- Novartis AG
- Takeda Pharmaceutical
- Seattle Genetics
- Progenics Pharmaceuticals
- Bayer Healthcare Pharmaceuticals
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into
- Breast Cancer
There are 15 Chapters to deeply display the global Antibody Drug Conjugates market.
Chapter 1, to describe Antibody Drug Conjugates Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Antibody Drug Conjugates, with sales, revenue, and price of Antibody Drug Conjugates, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Antibody Drug Conjugates, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Antibody Drug Conjugates market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Antibody Drug Conjugates sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source